FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to oncology, and aims at predicting the occurrence of local recurrences in patients with locally advanced breast cancer. Method involves taking into account the tumor characteristics and subsequent determination of the prognostic index by means of logistic regression analysis. Additionally, the parameters characterizing the degree of malignancy of the primary tumor, the presence of the germination of the tumor in the derma, the presence of angiolymphatic tumor invasion, the molecular subtype of the tumor, and further calculating the value of the regression equation Y by equation Y=(-3.83+2.20X1+1.31X2+27.18X3+1.06X4).
EFFECT: invention provides improved accuracy and information value of method.
1 cl, 4 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREDICTION OF ONSET OF LOCAL RECURRENCES IN SURGICAL SCARS IN UNICENTRIC INVASIVE DUCT BREAST CANCER IN PATIENTS WITH PRESERVED MENSTRUAL FUNCTION | 2012 |
|
RU2486518C1 |
METHOD FOR PREDICTING RISK OF BREAST CANCER PROGRESSION WITH UNDERLYING TAMOXIFEN TAKING INTO ACCOUNT EXPRESSION CHARACTERISTICS OF TUMOUR | 2023 |
|
RU2823488C1 |
METHOD OF PREDICTING HIGH RISK OF REGIONAL METASTASIS IN BREAST CANCER | 2023 |
|
RU2816441C1 |
METHOD FOR PREDICTION OF LYMPHATIC CANCER SPREAD ACCOMPANIED BY INVASIVE NONSPECIFIC TRIPLE-NEGATIVE BREAST CANCER | 2014 |
|
RU2558860C1 |
METHOD FOR PREDICTION OF HAEMATOGENOUS METASTASIS IN TRIPLE NEGATIVE INVASIVE NON-SPECIFIC BREAST CARCINOMA | 2014 |
|
RU2558863C1 |
METHOD FOR PREDICTION OF COMPLETE MORPHOLOGICAL REGRESSIONS IN PATIENTS SUFFERING TRIPLE-NEGATIVE RESECTABLE BREAST CANCER | 2014 |
|
RU2560707C1 |
METHOD OF PREDICTING EFFICIENCY OF NEOADJUVANT CHEMICAL THERAPY IN PATIENTS WITH RESECTABLE BASAL-LIKE TRIPLE-NEGATIVE BREAST CANCER | 2013 |
|
RU2538638C1 |
METHOD FOR PREDICTION OF FULL REGRESSION PROBABILITY DURING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH THREE-TIMES NEGATIVE MOLECULAR-GENETIC SUBTYPE OF BREAST CANCER | 2016 |
|
RU2623118C1 |
METHOD FOR PREDICTION OF DEGREE OF FULL REGRESSION PROBABILITY DURING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH LUMINAL MOLECULAR-GENETIC SUBTYPE OF BREAST CANCER | 2016 |
|
RU2632112C1 |
METHOD OF DIAGNOSING REGRESSION OF BREAST CANCER AFTER NEOADJUVANT DRUG THERAPY | 2022 |
|
RU2806299C1 |
Authors
Dates
2020-10-22—Published
2020-05-22—Filed